Selenium and coronary heart disease: A meta-analysis

Gemma Flores-Mateo, Ana Navas Acien, Roberto Pastor-Barriuso, Eliseo Guallar

Research output: Contribution to journalArticle

Abstract

Background: It is hypothesized that low selenium concentrations are associated with an increased risk of cardiovascular disease and that selenium supplements prevent coronary heart disease. Objective: The objective was to perform a meta-analysis on the association of selenium biomarkers with coronary heart disease endpoints in observational studies and on the efficacy of selenium supplements in preventing coronary heart disease endpoints in randomized trials. Design: The MEDLINE and the Cochrane Library databases were searched for studies conducted from 1966 through 2005. Relative risks were pooled by using an inverse-variance weighted random-effects model. Results: Twenty-five observational studies (14 cohort and 11 case-control studies) that measured blood or toenail selenium concentrations and 6 randomized trials that evaluated supplements containing selenium met our inclusion criteria. The pooled relative risk in a comparison of the highest with the lowest selenium concentration categories was 0.85 (95% CI: 0.74, 0.99) in cohort studies and 0.43 (0.29, 0.66) in case-control studies. In observational studies, a 50% increase in selenium concentrations was associated with a 24% (7%, 38%) reduction in coronary heart disease risk. In randomized trials, the pooled relative risk in a comparison of supplements containing selenium with placebo was 0.89 (0.68, 1.17). Conclusions: Selenium concentrations were inversely associated with coronary heart disease risk in observational studies. Because observational studies have provided misleading evidence for other antioxidants, the validity of this association is uncertain. Few randomized trials have addressed the cardiovascular efficacy of selenium supplementation, and their findings are still inconclusive. Evidence from large ongoing trials is needed to establish low selenium concentrations as a cardiovascular disease risk factor. Currently, selenium supplements should not be recommended for cardiovascular disease prevention.

Original languageEnglish (US)
Pages (from-to)762-773
Number of pages12
JournalAmerican Journal of Clinical Nutrition
Volume84
Issue number4
StatePublished - Oct 1 2006

Fingerprint

Selenium
meta-analysis
selenium
Coronary Disease
Meta-Analysis
observational studies
Observational Studies
relative risk
cardiovascular diseases
Cardiovascular Diseases
case-control studies
endpoints
coronary disease
Case-Control Studies
disease prevention
Nails
cohort studies
MEDLINE
Libraries
placebos

Keywords

  • Atherosclerosis
  • Coronary heart disease
  • Meta-analysis
  • Selenium
  • Systematic review

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Food Science

Cite this

Flores-Mateo, G., Navas Acien, A., Pastor-Barriuso, R., & Guallar, E. (2006). Selenium and coronary heart disease: A meta-analysis. American Journal of Clinical Nutrition, 84(4), 762-773.

Selenium and coronary heart disease : A meta-analysis. / Flores-Mateo, Gemma; Navas Acien, Ana; Pastor-Barriuso, Roberto; Guallar, Eliseo.

In: American Journal of Clinical Nutrition, Vol. 84, No. 4, 01.10.2006, p. 762-773.

Research output: Contribution to journalArticle

Flores-Mateo, G, Navas Acien, A, Pastor-Barriuso, R & Guallar, E 2006, 'Selenium and coronary heart disease: A meta-analysis', American Journal of Clinical Nutrition, vol. 84, no. 4, pp. 762-773.
Flores-Mateo G, Navas Acien A, Pastor-Barriuso R, Guallar E. Selenium and coronary heart disease: A meta-analysis. American Journal of Clinical Nutrition. 2006 Oct 1;84(4):762-773.
Flores-Mateo, Gemma ; Navas Acien, Ana ; Pastor-Barriuso, Roberto ; Guallar, Eliseo. / Selenium and coronary heart disease : A meta-analysis. In: American Journal of Clinical Nutrition. 2006 ; Vol. 84, No. 4. pp. 762-773.
@article{2927a8e062304f17aea86eef1555a33b,
title = "Selenium and coronary heart disease: A meta-analysis",
abstract = "Background: It is hypothesized that low selenium concentrations are associated with an increased risk of cardiovascular disease and that selenium supplements prevent coronary heart disease. Objective: The objective was to perform a meta-analysis on the association of selenium biomarkers with coronary heart disease endpoints in observational studies and on the efficacy of selenium supplements in preventing coronary heart disease endpoints in randomized trials. Design: The MEDLINE and the Cochrane Library databases were searched for studies conducted from 1966 through 2005. Relative risks were pooled by using an inverse-variance weighted random-effects model. Results: Twenty-five observational studies (14 cohort and 11 case-control studies) that measured blood or toenail selenium concentrations and 6 randomized trials that evaluated supplements containing selenium met our inclusion criteria. The pooled relative risk in a comparison of the highest with the lowest selenium concentration categories was 0.85 (95{\%} CI: 0.74, 0.99) in cohort studies and 0.43 (0.29, 0.66) in case-control studies. In observational studies, a 50{\%} increase in selenium concentrations was associated with a 24{\%} (7{\%}, 38{\%}) reduction in coronary heart disease risk. In randomized trials, the pooled relative risk in a comparison of supplements containing selenium with placebo was 0.89 (0.68, 1.17). Conclusions: Selenium concentrations were inversely associated with coronary heart disease risk in observational studies. Because observational studies have provided misleading evidence for other antioxidants, the validity of this association is uncertain. Few randomized trials have addressed the cardiovascular efficacy of selenium supplementation, and their findings are still inconclusive. Evidence from large ongoing trials is needed to establish low selenium concentrations as a cardiovascular disease risk factor. Currently, selenium supplements should not be recommended for cardiovascular disease prevention.",
keywords = "Atherosclerosis, Coronary heart disease, Meta-analysis, Selenium, Systematic review",
author = "Gemma Flores-Mateo and {Navas Acien}, Ana and Roberto Pastor-Barriuso and Eliseo Guallar",
year = "2006",
month = "10",
day = "1",
language = "English (US)",
volume = "84",
pages = "762--773",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "4",

}

TY - JOUR

T1 - Selenium and coronary heart disease

T2 - A meta-analysis

AU - Flores-Mateo, Gemma

AU - Navas Acien, Ana

AU - Pastor-Barriuso, Roberto

AU - Guallar, Eliseo

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Background: It is hypothesized that low selenium concentrations are associated with an increased risk of cardiovascular disease and that selenium supplements prevent coronary heart disease. Objective: The objective was to perform a meta-analysis on the association of selenium biomarkers with coronary heart disease endpoints in observational studies and on the efficacy of selenium supplements in preventing coronary heart disease endpoints in randomized trials. Design: The MEDLINE and the Cochrane Library databases were searched for studies conducted from 1966 through 2005. Relative risks were pooled by using an inverse-variance weighted random-effects model. Results: Twenty-five observational studies (14 cohort and 11 case-control studies) that measured blood or toenail selenium concentrations and 6 randomized trials that evaluated supplements containing selenium met our inclusion criteria. The pooled relative risk in a comparison of the highest with the lowest selenium concentration categories was 0.85 (95% CI: 0.74, 0.99) in cohort studies and 0.43 (0.29, 0.66) in case-control studies. In observational studies, a 50% increase in selenium concentrations was associated with a 24% (7%, 38%) reduction in coronary heart disease risk. In randomized trials, the pooled relative risk in a comparison of supplements containing selenium with placebo was 0.89 (0.68, 1.17). Conclusions: Selenium concentrations were inversely associated with coronary heart disease risk in observational studies. Because observational studies have provided misleading evidence for other antioxidants, the validity of this association is uncertain. Few randomized trials have addressed the cardiovascular efficacy of selenium supplementation, and their findings are still inconclusive. Evidence from large ongoing trials is needed to establish low selenium concentrations as a cardiovascular disease risk factor. Currently, selenium supplements should not be recommended for cardiovascular disease prevention.

AB - Background: It is hypothesized that low selenium concentrations are associated with an increased risk of cardiovascular disease and that selenium supplements prevent coronary heart disease. Objective: The objective was to perform a meta-analysis on the association of selenium biomarkers with coronary heart disease endpoints in observational studies and on the efficacy of selenium supplements in preventing coronary heart disease endpoints in randomized trials. Design: The MEDLINE and the Cochrane Library databases were searched for studies conducted from 1966 through 2005. Relative risks were pooled by using an inverse-variance weighted random-effects model. Results: Twenty-five observational studies (14 cohort and 11 case-control studies) that measured blood or toenail selenium concentrations and 6 randomized trials that evaluated supplements containing selenium met our inclusion criteria. The pooled relative risk in a comparison of the highest with the lowest selenium concentration categories was 0.85 (95% CI: 0.74, 0.99) in cohort studies and 0.43 (0.29, 0.66) in case-control studies. In observational studies, a 50% increase in selenium concentrations was associated with a 24% (7%, 38%) reduction in coronary heart disease risk. In randomized trials, the pooled relative risk in a comparison of supplements containing selenium with placebo was 0.89 (0.68, 1.17). Conclusions: Selenium concentrations were inversely associated with coronary heart disease risk in observational studies. Because observational studies have provided misleading evidence for other antioxidants, the validity of this association is uncertain. Few randomized trials have addressed the cardiovascular efficacy of selenium supplementation, and their findings are still inconclusive. Evidence from large ongoing trials is needed to establish low selenium concentrations as a cardiovascular disease risk factor. Currently, selenium supplements should not be recommended for cardiovascular disease prevention.

KW - Atherosclerosis

KW - Coronary heart disease

KW - Meta-analysis

KW - Selenium

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=33750616526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750616526&partnerID=8YFLogxK

M3 - Article

C2 - 17023702

AN - SCOPUS:33750616526

VL - 84

SP - 762

EP - 773

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 4

ER -